Girindus produces antiviral for trials
Canadian biotech company Replicor's lead antiviral drug candidate REP 9 is being produced by Girindus at the German API manufacturer's large-scale oligonucleotide plant in Cincinnati, Ohio, US. REP 9 is an oligonucleotide drug with potent broad spectrum antiviral activity. It also has the potential to treat pediatric and geriatric respiratory infections caused by the respiratory syncytial virus and the flu virus.
'Our new, cGMP oligonucleotide facility in Cincinnati allows us to meet our customers' needs for all phases of clinical trials,' said Fritz Link, ceo of Girindus. 'Girindus has also developed a proprietary solution phase synthesis technology, which targets production at ton scale.'
'It is critical to have a partner with a profound understanding and expertise in the manufacturing of this family of compounds,' added Dr Michel Bazinet, Replicor ceo. 'The potential offered by Girindus to use solution phase synthesis could allow Replicor to make substantial savings on its drug production costs in future.'